Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Honorio Bulos

Adolescent Medicine Dawsonville, GA Medical Doctor

NPI 1497712939 CMS profile 21929

300 Dawson Commons Cir, Ste 320, Dawsonville, GA 30534

Open in the dashboard

General payments

$2,692

165 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Honorio Bulos of Dawsonville, GA is reported in the CMS Open Payments database as having received $2,692 across 165 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Adolescent Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $473 34
2024 General $855 51
2023 General $509 33
2022 General $259 14
2021 General $226 12
2020 General $162 9
2019 General $207 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Honorio Bulos
  • Adolescent Medicine median
  • Middle half of Adolescent Medicine
  • National median

In program year 2025, general payments to Honorio Bulos were reported at $473. Among 914 Adolescent Medicine profiles paid that year, the median was $100 and the middle half received between $40 and $207.

Show as a table
Year Honorio Bulos Adolescent Medicine median Middle half National median
2019 $207 $95 $36–$198 $163
2020 $162 $50 $23–$111 $114
2021 $226 $67 $27–$179 $132
2022 $259 $79 $29–$189 $149
2023 $509 $100 $39–$194 $160
2024 $855 $93 $38–$195 $164
2025 $473 $100 $40–$207 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Supernus Pharmaceuticals, Inc. $635 27 payments
  2. Ironshore Pharmaceuticals Inc. $573 34 payments
  3. Corium, Inc. $383 46 payments
  4. ALK-Abello, Inc $268 13 payments
  5. Sanofi Pasteur Inc. $155 8 payments
  6. Tris Pharma Inc $146 8 payments
  7. Cranial Technologies, Inc $131 8 payments
  8. Pfizer Inc. $47 2 payments
  9. GlaxoSmithKline, LLC. $41 2 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $41 2 payments
  11. Other $272 15 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,692 165 payments
Products named General payments · program years 2019–2025
  1. Azstarys $383 46 payments
  2. Qelbree Viloxazine Hydrochloride $374 17 payments
  3. Grastek $268 13 payments
  4. Odactra $268 13 payments
  5. JORNAY PM Central Nervous System Stimulant $262 18 payments
  6. QELBREE Psychology $261 10 payments
  7. JORNAY PM Central Nervous Stimulant ADHD $229 12 payments
  8. Ragwitek $181 8 payments
  9. Doc Band $131 8 payments
  10. BEYFORTUS $128 6 payments
  11. Other $1,269 68 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

165 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Adolescent Medicine in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record